Mohammad Alashqar/LinkedIn
May 20, 2026, 12:42
Mohammad Alashqar: Cost-Effectiveness of Fitusiran Prophylaxis in Severe Hemophilia A Without Inhibitors
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
”Proud to present poster N 3044 at ISPOR – The Professional Society for Health Economics and Outcomes Research 2026 on the ‘cost-effectiveness of fitusiran prophylaxis versus FVIII prophylaxis or on-demand therapy for patients with severe hemophilia A without inhibitors.’
Grateful to represent The Ohio State University College of Pharmacy and contribute to discussions advancing HEOR, value assessment, and evidence-based care.”
Stay updated with Hemostasis Today.
-
May 20, 2026, 13:10Ingmar Schön: Our paper on Thrombin-Driven Regulation of Platelet Contractility Is Now Live
-
May 20, 2026, 12:45Sergio Emanuel Kaiser: Day 6 of Road to EAS Congress 2026 challenge to So Me ambassadors
-
May 20, 2026, 12:27Atul Gupta: Patients Share Their Personal Stroke Stories to Help Raise Public Awareness
-
May 20, 2026, 12:06Nita Radhakrishnan: The 2nd Edition of the IAP-PHO Guidelines for Thalassemia Is Now Live
-
May 20, 2026, 11:48Stuart T. Haines: Pharmacist-Led Warfarin Management Improves Therapeutic Control in HeartMate 3 LVAD Patients
-
May 20, 2026, 11:41Heba Youssef: When to Start Anticoagulation Therapy After Intracerebral Hemorrhage
-
May 20, 2026, 11:19Javier Pérez Monreal: Combining Endovenous Laser and Foam Therapy in Recurrent Varicose Veins
-
May 20, 2026, 11:01Maria Cherska: Exploring the Role of Fucoidan in Metabolic Liver Disease
-
May 20, 2026, 10:40Sameh Sayfo: Join Two Live Webinars on the New AHA Guidelines